- Home
- OXSQ vs AGEN Comparison
OXSQ vs AGEN Comparison
Compare OXSQ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- AGEN
- Stock Information
- Founded
- OXSQ 2003
- AGEN 1994
- Country
- OXSQ United States
- AGEN United States
- Employees
- OXSQ N/A
- AGEN N/A
- Industry
- OXSQ Blank Checks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OXSQ Finance
- AGEN Health Care
- Exchange
- OXSQ Nasdaq
- AGEN Nasdaq
- Market Cap
- OXSQ 144.4M
- AGEN 123.6M
- IPO Year
- OXSQ N/A
- AGEN 2000
- Fundamental
- Price
- OXSQ $1.92
- AGEN $3.94
- Analyst Decision
- OXSQ
- AGEN Buy
- Analyst Count
- OXSQ 0
- AGEN 2
- Target Price
- OXSQ N/A
- AGEN $14.50
- AVG Volume (30 Days)
- OXSQ 757.9K
- AGEN 457.8K
- Earning Date
- OXSQ 11-04-2025
- AGEN 11-10-2025
- Dividend Yield
- OXSQ 21.99%
- AGEN N/A
- EPS Growth
- OXSQ N/A
- AGEN N/A
- EPS
- OXSQ N/A
- AGEN N/A
- Revenue
- OXSQ $40,142,565.00
- AGEN $101,706,000.00
- Revenue This Year
- OXSQ N/A
- AGEN $60.49
- Revenue Next Year
- OXSQ $0.12
- AGEN N/A
- P/E Ratio
- OXSQ N/A
- AGEN N/A
- Revenue Growth
- OXSQ N/A
- AGEN N/A
- 52 Week Low
- OXSQ $1.56
- AGEN $1.38
- 52 Week High
- OXSQ $2.96
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- OXSQ 56.13
- AGEN 45.45
- Support Level
- OXSQ $1.83
- AGEN $3.63
- Resistance Level
- OXSQ $1.95
- AGEN $4.11
- Average True Range (ATR)
- OXSQ 0.06
- AGEN 0.21
- MACD
- OXSQ 0.02
- AGEN -0.00
- Stochastic Oscillator
- OXSQ 85.42
- AGEN 33.73
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).